Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Origen Therapeutics Inc.

Latest From Origen Therapeutics Inc.

The Protein Production Challenge

Growth of the biopharmaceutical market is going to create critical shortages in protein manufacturing capacity with severe consequences for pharmaceutical companies' ability to deliver products and meet rising market expectations. Companies whose pipelines are heavily reliant on expression systems with limited capacity are particularly vulnerable and should now be making strategic make/buy/collaborate decisions. Indeed, in the short term as capacity tightens, contract manufacturing organizations will gain greater leverage, enabling them to negotiate more strategic business relationships with higher financial returns. In the longer term, however, innovator companies are looking beyond cell culture to alternative technologies such as transgenic animals as a future production platform, in part, because they provide greater flexibility.
BioPharmaceutical Business Strategies

Antibody Opportunities

Antibodies are driving valuations at many public companies--and the aspirations of start-ups with new means of generating, tailoring and harnessing the proteins.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Origen Therapeutics Inc.
  • Senior Management
  • Robert Kay, PhD, CEO
    Karen Chapman, PhD, VP, Corp. Dev.
    Phil Leighton, Dir., Research
  • Contact Info
  • Origen Therapeutics Inc.
    Phone: (650) 827-0200
    1450 Rollins Rd.
    Burlingame, CA 94010-2307